Mobocertinib

Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test

Retrieved on: 
Wednesday, June 14, 2023
KRAS, CE, AACR, Takeda, Severance Hospital, ESR1, NGS, RT-PCR, Cancer, Business, BRAF, Janssen, Mutation, Research, PIK3CA, Certification, Strategy, MRD, Plasma, Korean Ministry of Culture, Bio-Rad Laboratories, Hospital, Acquisition, Patient, European, EGFR, Colorectal cancer, IVD, Samsung Medical Center, Amivantamab, POLE, Recurrence, PCR, Mobocertinib, Medical device, NSCLC, Food

SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.

Key Points: 
  • SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.
  • This product is a companion diagnostic test designed to detect EGFR mutations commonly found in NSCLC patients and guide the selection of appropriate targeted anticancer therapies based on the test results.
  • Compared to existing EGFR mutation tests using RT-PCR, this product demonstrates significantly higher sensitivity.
  • This is the second EGFR mutation test for which Gencurix has obtained approval.

Global Rare Disease Therapeutics Market Report 2023: Players Include AbbVie, Novo Nordisk, Sanofi, Bayer, Amgen and Eisai - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 5, 2023
Biotechnology, Pharmaceutical, Health, Orphan Drug Act of 1983, CDER, COVID-19, Therapy, Disease, NORD, Bone marrow, DSM-IV codes, Pharmacy, Loncastuximab tesirine, Infection, National Organization for Rare Disorders, USD, Competition, Market, Malignancy, Administration, EURORDIS, Rare, Patient, Laboratory, European Organization for Quality, European, Center for Drug Evaluation and Research, Route of administration, Knowledge, Pharmaceutical Research and Manufacturers of America, Global Genes, D, Pharmaceutical industry, Research, Mobocertinib

The global rare disease therapeutics market is projected to undergo a vigorous expansion in the coming years.

Key Points: 
  • The global rare disease therapeutics market is projected to undergo a vigorous expansion in the coming years.
  • The market for treating rare diseases will expand as the number of rare diseases rises.
  • Therefore, continued market expansion prospects will arise from research into unmet rare disease treatments in the future.
  • According to clinicaltrials.gov, there are around 2,615 studies related to rare disease therapeutics which are in different phases of development across different parts of the globe.